Olga Zaikova1, Kirsten Sundby Hall2, Emelie Styring3, Mikael Eriksson4, Clement S Trovik5, Peter Bergh6, Bodil Bjerkehagen7, Mikael Skorpil8, Harald Weedon-Fekjaer9, Henrik C F Bauer10. 1. Department of Orthopedics, Oslo University Hospital, The Norwegian Radium Hospital, Norway. 2. Department of Oncology, Oslo University Hospital, The Norwegian Radium Hospital, Norway. 3. Department of Orthopedics, Lund University and Skane University Hospital, Lund, Sweden. 4. Department of Oncology, Skane University Hospital, and Lund University, Lund, Sweden. 5. Department of Orthopaedics, Haukeland University Hospital, Bergen, Norway. 6. Department of Orthopaedics, Sahlgren University Hospital, Gothenburg, Sweden. 7. Department of Pathology, Oslo University Hospital, The Norwegian Radium Hospital, Norway. 8. Department of Molecular Medicine and Surgery, Diagnostic Radiology, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden. 9. Oslo Center for Biostatistics and Epidemiology, Research Support Services, Oslo University Hospital, Oslo, Norway. 10. Department of Molecular Medicine and Surgery, Section for Orthopaedics and Sports Medicine, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden.
Abstract
AIMS: The objectives of this study were to present changes in referral patterns, treatment and survival in patients with high-grade malignant bone sarcoma in Sweden and Norway based on data in the Scandinavian Sarcoma Group (SSG) Central Register. METHOD: Data on 1,437 patients with diagnosis 1986-2010 was analyzed. RESULTS: Osteosarcoma was the most frequentl diagnosis (45%), followed by Ewing sarcoma (21%) and chondrosarcoma (17%). Thirty-one percent of Swedish and 41% of Norwegian patients had tumors in the axial skeleton. Eighty-six percent of extremity tumors and 66% of axial tumors were referred to a sarcoma center prior to unplanned surgery or biopsy. During the past decade, limb salvage surgery has risen from under 50% to over 80%. Five-year overall survival in non-metastatic osteosarcoma was 70% for extremity tumors, and 35% for axial tumors. No improvement in osteosarcoma survival was observed during the last decade. Five-year survival in Ewing sarcoma improved from 50% to 69%. CONCLUSION: Referral patterns in bone sarcomas have improved. However, greater efforts should be dedicated to improving referral of patients with possible tumors in the axial skeleton to multidisciplinary teams (MDTs). Overall survival of patients with high-grade malignant bone sarcomas in Sweden and Norway is in line with other reports.
AIMS: The objectives of this study were to present changes in referral patterns, treatment and survival in patients with high-grade malignant bone sarcoma in Sweden and Norway based on data in the Scandinavian Sarcoma Group (SSG) Central Register. METHOD: Data on 1,437 patients with diagnosis 1986-2010 was analyzed. RESULTS:Osteosarcoma was the most frequentl diagnosis (45%), followed by Ewing sarcoma (21%) and chondrosarcoma (17%). Thirty-one percent of Swedish and 41% of Norwegian patients had tumors in the axial skeleton. Eighty-six percent of extremity tumors and 66% of axial tumors were referred to a sarcoma center prior to unplanned surgery or biopsy. During the past decade, limb salvage surgery has risen from under 50% to over 80%. Five-year overall survival in non-metastatic osteosarcoma was 70% for extremity tumors, and 35% for axial tumors. No improvement in osteosarcoma survival was observed during the last decade. Five-year survival in Ewing sarcoma improved from 50% to 69%. CONCLUSION: Referral patterns in bone sarcomas have improved. However, greater efforts should be dedicated to improving referral of patients with possible tumors in the axial skeleton to multidisciplinary teams (MDTs). Overall survival of patients with high-grade malignant bone sarcomas in Sweden and Norway is in line with other reports.
Authors: Joshua M Lawrenz; Joseph Featherall; Gannon L Curtis; Jaiben George; Yuxuan Jin; Peter M Anderson; Dale R Shepard; John D Reith; Brian P Rubin; Lukas M Nystrom; Nathan W Mesko Journal: Sarcoma Date: 2020-05-04
Authors: Eline de Heus; Vivian Engelen; Irene Dingemans; Carol Richel; Marga Schrieks; Jan Maarten van der Zwan; Marc G Besselink; Mark I van Berge Henegouwen; Carla M L van Herpen; Saskia F A Duijts Journal: Orphanet J Rare Dis Date: 2021-06-01 Impact factor: 4.123